EP1153022A1 - Inhibiteurs de protease - Google Patents

Inhibiteurs de protease

Info

Publication number
EP1153022A1
EP1153022A1 EP00910222A EP00910222A EP1153022A1 EP 1153022 A1 EP1153022 A1 EP 1153022A1 EP 00910222 A EP00910222 A EP 00910222A EP 00910222 A EP00910222 A EP 00910222A EP 1153022 A1 EP1153022 A1 EP 1153022A1
Authority
EP
European Patent Office
Prior art keywords
methyl
butyl
amide
carboxylic acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910222A
Other languages
German (de)
English (en)
Other versions
EP1153022A4 (fr
Inventor
Robert Wells Marquis, Jr.
Daniel Frank Veber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1153022A1 publication Critical patent/EP1153022A1/fr
Publication of EP1153022A4 publication Critical patent/EP1153022A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/18—Eight-membered rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates in general to 7-14 membered ring ether protease inhibitors, particularly such inhibitors of cysteine and serine proteases, more particularly compounds which inhibit cysteine proteases, even more particularly compounds which inhibit cysteine proteases of the papain superfamily, yet more particularly compounds which inhibit cysteine proteases of the cathepsin family, most particularly compounds which inhibit cathepsin K.
  • Such compounds are particularly useful for treating diseases in which cysteine proteases are implicated, especially diseases of excessive bone or cartilage loss, e.g., osteoporosis, periodontitis, and arthritis.
  • Cathepsins are a family of enzymes which are part of the papain superfamily of cysteine proteases. Cathepsins B, H, L, N and S have been described in the literature. Recently, cathepsin K polypeptide and the cDNA encoding such polypeptide were disclosed in U.S. Patent No. 5,501,969 (called cathepsin O therein). Cathepsin K has been recently expressed, purified, and characterized. Bossard, M. J., et al., (1996) J. Biol. Chem. 271, 12517-12524; Drake, F.H., et al., (1996) J. Biol. Chem. 271, 1251 1-12516; Brom e, D., et al., (1996) J. Biol. Chem. 271, 2126-2132.
  • Cathepsin K has been variously denoted as cathepsin O or cathepsin 02 in the literature.
  • the designation cathepsin K is considered to be the more appropriate one.
  • Cathepsins function in the normal physiological process of protein degradation in animals, including humans, e.g., in the degradation of connective tissue. However, elevated levels of these enzymes in the body can result in pathological conditions leading to disease. Thus, cathepsins have been implicated as causative agents in various disease states, including but not limited to, infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei brucei, and Crithidia fusiculata; as well as in schistosomiasis, malaria, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, and the like.
  • Bone is composed of a protein matrix in which spindle- or plate-shaped crystals of hydroxyapatite are incorporated.
  • Type I collagen represents the major structural protein of bone comprising approximately 90% of the protein matrix. The remaining 10% of matrix is composed of a number of non-collagenous proteins, including osteocalcin, proteoglycans, osteopontin, osteonectin, thrombospondin, fibronectin, and bone sialoprotein.
  • Skeletal bone undergoes remodelling at discrete foci throughout life. These foci, or remodelling units, undergo a cycle consisting of a bone resorption phase followed by a phase of bone replacement.
  • Bone resorption is carried out by osteoclasts, which are multinuclear cells of hematopoietic lineage.
  • the osteoclasts adhere to the bone surface and form a tight sealing zone, followed by extensive membrane ruffling on their apical (i.e., resorbing) surface.
  • the low pH of the compartment dissolves hydroxyapatite crystals at the bone surface, while the proteolytic enzymes digest the protein matrix. In this way, a resorption lacuna, or pit, is formed.
  • osteoblasts lay down a new protein matrix that is subsequently mineralized.
  • disease states such as osteoporosis and Paget's disease
  • the normal balance between bone resorption and formation is disrupted, and there is a net loss of bone at each cycle.
  • this leads to weakening of the bone and may result in increased fracture risk with minimal trauma.
  • inhibitors of cysteine proteases are effective at inhibiting osteoclast-mediated bone resorption, and indicate an essential role for a cysteine proteases in bone resorption. For example, Delaisse, et al., Biochem.
  • cystatin an endogenous cysteine protease inhibitor
  • cystatin an endogenous cysteine protease inhibitor
  • Other studies such as by Delaisse, et al., Bone, 1987, 8, 305, Hill, et al., J. Cell. Biochem., 1994, 56, 1 18, and Everts, et al, J. Cell. Physioi, 1992, 150, 221 , also report a correlation between inhibition of cysteine protease activity and bone resorption. Tezuka, et al., J. Biol. Chem., 1994, 269, 1106, Inaoka, et al, Biochem. Biophys. Res.
  • cathepsin K may provide an effective treatment for diseases of excessive bone loss, including, but not limited to, osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease.
  • Cathepsin K levels have also been demonstrated to be elevated in chondroclasts of osteoarthritic synovium.
  • selective inhibition of cathepsin K may also be useful for treating diseases of excessive cartilage or matrix degradation, including, but not limited to, osteoarthritis and rheumatoid arthritis.
  • Metastatic neoplastic cells also typically express high levels of proteolytic enzymes that degrade the surrounding matrix.
  • selective inhibition of cathepsin K may also be useful for treating certain neoplastic diseases.
  • cysteine protease inhibitors are known. Palmer, (1995) J. Med. Chem., 38, 3193, disclose certain vinyl sulfones which irreversibly inhibit cysteine proteases, such as the cathepsins B, L, S, 02 and cruzain. Other classes of compounds, such as aldehydes, nitriles, -ketocarbonyl compounds, halomethyl ketones, diazomethyl ketones, (acyloxy)methyl ketones, ketomethylsulfonium salts and epoxy succinyl compounds have also been reported to inhibit cysteine proteases. See Palmer, id, and references cited therein.
  • U.S. Patent No. 4,518,528 discloses peptidyl fluoromethyl ketones as irreversible inhibitors of cysteine protease.
  • Published International Patent Application No. WO 94/04172, and European Patent Application Nos. EP 0 525 420 Al, EP 0 603 873 Al , and EP 0 61 1 756 A2 describe alkoxymethyl and mercaptomethyl ketones which inhibit the cysteine proteases cathepsins B, H and L.
  • PCT/US94/08868 and and European Patent Application No. EP 0 623 592 Al describe alkoxymethyl and mercaptomethyl ketones which inhibit the cysteine protease IL-l convertase. Alkoxymethyl and mercaptomethyl ketones have also been described as inhibitors of the serine protease kininogenase (International Patent Application No.
  • Azapeptides which are designed to deliver the azaamino acid to the active site of serine proteases, and which possess a good leaving group, are disclosed by Elmore et al., Biochem. J., 1968, 707, 103, Garker et al, Biochem. J., 1974, 139, 555, Gray et al,
  • cysteine protease inhibitors have been identified.
  • these known inhibitors are not considered suitable for use as therapeutic agents in animals, especially humans, because they suffer from various shortcomings. These shortcomings include lack of selectivity, cytotoxicity, poor solubility, and overly rapid plasma clearance.
  • An object of the present invention is to provide 7-14 membered ring ether protease inhibitors, particularly such inhibitors of cysteine and serine proteases, more particularly such compounds which inhibit cysteine proteases, even more particularly such compounds which inhibit cysteine proteases of the papain superfamily, yet more particularly such compounds which inhibit cysteine proteases of the cathepsin family, most particularly such compounds which inhibit cathepsin K, and which are useful for treating diseases which may be therapeutically modified by altering the activity of such proteases.
  • this invention provides a compound according to
  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to Formula I and a pharmaceutically acceptable carrier, diluent or excipient.
  • this invention provides intermediates useful in the preparation of the compounds of Formula I.
  • this invention provides a method of treating diseases in which the disease pathology may be therapeutically modified by inhibiting proteases, particularly cysteine and serine proteases, more particularly cysteine proteases, even more particularly cysteine proteases of the papain superfamily, yet more particularly cysteine proteases of the cathepsin family, most particularly cathepsin K.
  • the compounds of this invention are especially useful for treating diseases characterized by bone loss, such as osteoporosis and gingival diseases, such as gingivitis and periodontitis, or by excessive cartilage or matrix degradation, such as osteoarthritis and rheumatoid arthritis.
  • the present invention provides compounds of Formula I:
  • A is C(0) or CH(OH); R s
  • R' is selected from the group consisting of: H, Ct .galkyl, Ar-C()-6alkyl, and Het- C " o-6alkyl;
  • R" is selected from the group consisting of: H, C j .galkyl, Ar-C ⁇ -6 a Ikyl, and Het-
  • R' is selected from the group consisting of: H, Cj.galkyl, C3_6cycloalkyl-C()- galkyl, Ar-Cg-galkyl, and Het-Cg-galkyl;
  • R is selected from the group consisting of: H, Cj.galkyl, C3_6cycloalkyl-Co_ 6 alkyl, Ar-C 0 . 6 alkyl, Het-C 0 . 6 alkyl, R 4 C(0)-, R 4 C(S)-, R 4 S0 2 -, R 4 OC(0)-, R 4 R 7 NC(0)-, R 4 R 7 NC(S)-, R 7 HNCH(R 7 )C(0)-, and R 4 OC(0)NR 7 CH(R 7 )C(0)-; R 4 is selected from the group consisting of: C j . ⁇ alkyl, C3_6cycloalkyl-Co_6alkyl,
  • R-> is selected from the group consisting of: H, Cj. ⁇ alkyl, Ar-C ⁇ -6 a lkyl, and Het- C 0 _6alkyl;
  • R" and R 7 are selected from the group consisting of: H, Cj.galkyl, Ar-C()-6alkyl, and Het-Co_6alkyl;
  • A is C(O).
  • compounds according to Claim 1 wherein R" and R'" are both H.
  • n is 1 and L is 0 or 1.
  • L is 0 or 1 ; and R" and R"' are both H.
  • A is C(O);
  • L is 1 ;
  • R', R" and R'" are independently H;
  • R 3 is R 4 C(0)-;
  • R 4 is selected from the group consisting of: Ar-Co_6alkyl and Het-C () -6 a lkyl, preferably: naphthylenyl, especially naphthylen-2-yl; benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl; 3-methyl-benzofuranyl, especially3-methyl-benzofuran-2-yl; quinoxalinyl, especially, quinoxaline-2-yl; benzofuranyl, especially benzofuran-2-yl; benzo[b]thiophenyl, especially benzo[b]thiophene-2-yl;
  • 5-methyl-benzo[b]thiophenyl especially 5-methyl-benzo[b]thiophene-2-yl
  • 5,6-dimethoxy-benzofuranyl especially 5,6-dimethoxy-benzofuran-2-yl
  • Benzo[b]thiophene-2-carboxylic acid [(S)-3-methy 1- 1 -((S)-3-oxo-3,4,5,8-tetrahydro-2H- oxocin-4-ylcarbamoyl)-butyl]-amide; 3-Methyl-benzofuran-2-carboxylic acid [(S)-3-methyl-l-((S)-3-oxo-3,4,5,8-tetrahydro-2H- oxocin-4-ylcarbamoyl)-butyl]-amide;
  • the present invention includes all hydrates, solvates, complexes and prodrugs of the compounds of this invention.
  • Prodrugs are any covalently bonded compounds which release the active parent drug according to Formula I in vivo. If a chiral center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein.
  • Inventive compounds containing a chiral center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
  • any substituent at any one occurrence in Formula I or any subformula thereof is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise.
  • Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of the present invention. In general, the amino acid abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in Eur. J. Biochem., 158, 9 (1984).
  • proteases are enzymes that catalyze the cleavage of amide bonds of peptides and proteins by nucleophilic substitution at the amide bond, ultimately resulting in hydrolysis.
  • proteases include: cysteine proteases, serine proteases, aspartic proteases, and metalloproteases.
  • the compounds of the present invention are capable of binding more strongly to the enzyme than the substrate and in general are not subject to cleavage after enzyme catalyzed attack by the nucleophile. They therefore competitively prevent proteases from recognizing and hydrolyzing natural substrates and thereby act as inhibitors.
  • amino acid refers to the D- or L- isomers of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
  • C]-6 a lkyl as applied herein is meant to include substituted and unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof.
  • C ⁇ a lkyl means that no alkyl group is present in the moiety.
  • Ar-Co a lkyl is equivalent to Ar.
  • C3-6cycloalkyl as applied herein is meant to include substituted and unsubstituted cyclopropane, cyclobutane, cyclopentane and cyclohexane.
  • C2-6 a lkenyl as applied herein means an alkyl group of 2 to 6 carbons wherein a carbon-carbon single bond is replaced by a carbon-carbon double bond.
  • C2-6 a lkenyl includes ethylene, 1-propene, 2-propene, 1-butene, 2-butene, isobutene and the several isomeric pentenes and hexenes. Both cis and trans isomers are included.
  • C2-6 a lkynyl means an alkyl group of 2 to 6 carbons wherein one carbon-carbon single bond is replaced by a carbon-carbon triple bond.
  • C2-6 a lkynyl includes acetylene, 1- propyne, 2-propyne, 1-butyne, 2-butyne, 3-butyne and the simple isomers of pentyne and hexyne.
  • Halogen means F, Cl, Br, and I.
  • Ar or aryl means phenyl or naphthyl, optionally substituted by one or more of Ph-C 0 _6alkyl; Het-C 0 _6 a lkyl; C ⁇ _6 a lkoxy; Ph-C()-6 a lkoxy; Het-Co_6 a lkoxy; OH, (CHf) ⁇ .
  • Het represents a stable 5- to 7-membered monocyclic, a stable 7- to 10-membered bicyclic, or a stable 11- to 18-membered tricyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure, and may optionally be substituted with one or two moieties selected from C 0 _6Ar, C]_6alkyl, OR', N(R') 2 , SR', CF 3 , N0 2 , CN, C0 2 R', CON(R'), F, Cl, Br and I, where R' is phenyl, naphthyl, or C ⁇ _6alkyl.
  • heterocycles include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2- oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl, quinuclidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, benzoxazolyl, furyl, pyranyl, tetrahydrofuryl, tetrahydropyr
  • CQ denotes the absence of the substituent group immediately following; for instance, in the moiety ArCo_6 a lkyl, when C is 0, the substituent is Ar, e.g., phenyl. Conversely, when the moiety ArC()-6 a lkyl is identified as a specific aromatic group, e.g., phenyl, it is understood that C is 0.
  • t-Bu refers to the tertiary butyl radical
  • Boc refers to the t-butyloxycarbonyl radical
  • Fmoc refers to the fluorenylmethoxycarbonyl radical
  • Ph refers to the phenyl radical
  • Cbz refers to the benzyloxycarbonyl radical.
  • EDC N-ethyl- N'(dimethylaminopropyl)-carbodiimide
  • DMF dimethyl formamide
  • DMSO dimethyl sulfoxide
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • N-Boc-(d,l)-allylglycine (1) may be converted to the bromomethyl ketone 2 by treatment with /s ⁇ -butylchloroformate followed by treatment of the intermediate mixed anhydride with diazomethane to provide the diazomethyl ketone (not shown). Treatment of the diazomethyl ketone with 30% HBr/HOAc provides the bromothylketone 2.
  • Conversion of the bromomethylketone 2 to the hydroxymethylketone 3 may be effected by treatment of 2 with benzoylformic acid followed by saponification of the intermediate formate ester with an aqueous base such as potassium hydrogen carbonate.
  • Etherification of alcohol 3 may be effected by treatment with allyliodide and silver oxide to provide the ether 4.
  • Reduction of 4 with a reducing agent common to the art such as sodium borohydride followed by protection with dimethoxypropane provides the diene 5.
  • the diene 5 may be cyclised to the 3,4,5, 8-tetrahydro-2H-oxocin 6 by treatment with an olefin metathesis catalyst such as bis(tricyclohexylphosphine)benzylidine ruthenium(IV)dichloride.
  • an olefin metathesis catalyst such as bis(tricyclohexylphosphine)benzylidine ruthenium(IV)dichloride.
  • Removal of the acid labile protecting groups may be effected with and acid such as HCl or TFA to provide the amino alcohol 7.
  • Amino alcohol 7 may be acylated with an acid such as N-Boc-leucine in the presence of a coupling agent common to the art such as EDC. Removal of the N-Boc protecting group may be effected with an acid such as HCl or TFA to provide the amine salt 8.
  • the amine salt 8 may be acylated with an acid such as 2-naphthoic acid in the presence of a coupling agent such as EDC.
  • the resulting alcohol (not shown) may be oxidized to the ketone 9 with an oxidizing agent common to the art such as Dess-Martin periodoindane or Swern conditions.
  • an oxidizing agent common to the art such as Dess-Martin periodoindane or Swern conditions.
  • Reagents and conditions a.) iso-butylchloroformate, THF, NMM; CH2N2; 30% HBr/HOAc; b.) benzoylformic acid, KF, DMF; c.) KHCO3, THF, H 2 0; d.) allyliodide, Ag 2 0, CH 2 C1 2 , reflux; e.) NaBH 4 , CH3OH; f.) 2,2- dimethoxy propane, CSA, CH 2 C1 2 , reflux; g.) bis(tricyclohexylphosphine) benzylidine ruthenium(IV)dichloride, toluene, 80°C; h.) TFA, CH 2 C1 2 ; i.) TFA, THF, H 2 0; j.) N-Boc-leucine, EDC, NMM, CH 2 C1 2 ; k.) TFA, CH 2 C1 2 ; 1.
  • the saturated derivatives may be prepared as outlined in Scheme 2.
  • Coupling of amino alcohol 10 with Cbz-Ieucine in the presence of a coupling agent such as EDC provides the amide 11.
  • Reduction of the olefin and concomitant removal of the Cbz protecting group with 10% Pd on carbon in the presence of hyrogen gas gives 12.
  • Coupling followed by oxidation with an oxidant such as Dess-Martin periodinane provides the ketone Scheme 2
  • Reagents and conditions a.) CBz-leucine, EDC; b.) 10% Pd/C, H,; c.) benzofuran-2-carboxylic acid, EDC; d.) Dess-Martin periodinane.
  • Ring closing olefin metathesis of 16 with bis(tricyclohexylphosphine)benzylidine ruthenium(IV)dichloride provides the intermediate oxepin (not shown) which is reduced with hydrogen in the presence of 10% Pd/C to provide the oxepane 17.
  • Saponification of the carbamate may be effected by treatment of 17 with lithium hydroxide followed by treatment with di-tert- butyldicarbonate to provide the tert-butyl carbamate (not shown). Removal of the tert- butoxycarbonyl protecting group under standard acidic conditions provided the amino alcohol derivative 18.
  • Coupling of amino alcohol 18 with N-Boc-leucine may be effected by coupling reagents common in the art such as EDC. Removal of the tert-butoxycarbonyl protecting group under standard acidic conditions provided 19. Coupling of 19 with benzo[b]thiophene-2-carboxylic acid in the presence of a coupling agent such as EDC followed by oxidation with an oxidizing agent such as Dess-Martin periodinane provides the ketone derivative 20.
  • Coupling methods to form amide bonds herein are generally well known to the art.
  • the methods of peptide synthesis generally set forth by Bodansky et al., THE PRACTICE OF PEPTIDE SYNTHESIS, Springer- Verlag, Berlin, 1984; E. Gross and J. Meienhofer, THE PEPTIDES, Vol. 1, 1-284 (1979); and J.M. Stewart and J.D. Young, SOLID PHASE PEPTIDE SYNTHESIS, 2d Ed., Pierce Chemical Co., Rockford, 111., 1984. are generally illustrative of the technique and are incorporated herein by reference.
  • amino protecting groups generally refers to the Boc, acetyl, benzoyl, Fmoc and Cbz groups and derivatives thereof as known to the art. Methods for protection and deprotection, and replacement of an amino protecting group with another moiety are well known.
  • Acid addition salts of the compounds of Formula I are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable.
  • Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine.
  • Cations such as Li + , Na + , K + , Ca ++ , Mg ++ and NH4 + are specific examples of cations present in pharmaceutically acceptable salts.
  • Halides, sulfate, phosphate, alkanoates (such as acetate and trifluoroacetate), benzoates, and sulfonates (such as mesylate) are examples of anions present in pharmaceutically acceptable salts.
  • compositions of the compounds of Formula I may be used in the manufacture of a medicament.
  • Pharmaceutical compositions of the compounds of Formula I prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • these compounds may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • Liquid carriers include syrup, peanut oil, olive oil, saline and water.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
  • Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • the compounds of Formula I are useful as protease inhibitors, particularly as inhibitors of cysteine and serine proteases, more particularly as inhibitors of cysteine proteases, even more particularly as inhibitors of cysteine proteases of the papain superfamily, yet more particularly as inhibitors of cysteine proteases of the cathepsin family, most particularly as inhibitors of cathepsin K.
  • the present invention also provides useful compositions and formulations of said compounds, including pharmaceutical compositions and formulations of said compounds.
  • the present compounds are useful for treating diseases in which cysteine proteases are implicated, including infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia fusiculata; as well as in schistosomiasis, malaria, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy; and especially diseases in which cathepsin K is implicated, most particularly diseases of excessive bone or cartilage loss, including osteoporosis, gingival disease including gingivitis and periodontitis, arthritis, more specifically, osteoarthritis and rheumatoid arthritis, Paget's disease; hypercalcemia of malignancy, and metabolic bone disease.
  • Metastatic neoplastic cells also typically express high levels of proteolytic enzymes that degrade the surrounding matrix, and certain tumors and metastatic neoplasias may be effectively treated with the compounds of this invention.
  • the present invention also provides methods of treatment of diseases caused by pathological levels of proteases, particularly cysteine and serine proteases, more particularly cysteine proteases, even more particularly as inhibitors of cysteine proteases of the papain superfamily, yet more particularly cysteine proteases of the cathepsin family, which methods comprise administering to an animal, particularly a mammal, most particularly a human in need thereof a compound of the present invention.
  • the present invention especially provides methods of treatment of diseases caused by pathological levels of cathepsin K, which methods comprise administering to an animal, particularly a mammal, most particularly a human in need thereof an inhibitor of cathepsin K, including a compound of the present invention.
  • the present invention particularly provides methods for treating diseases in which cysteine proteases are implicated, including infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia fusiculata; as well as in schistosomiasis, malaria, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy, , and especially diseases in which cathepsin K is implicated, most particularly diseases of excessive bone or cartilage loss, including osteoporosis, gingival disease including gingivitis and periodontitis, arthritis, more specifically, osteoarthritis and rheumatoid arthritis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease.
  • diseases in which cysteine proteases are implicated, including infections by pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia fusiculat
  • This invention further provides a method for treating osteoporosis or inhibiting bone loss which comprises internal administration to a patient of an effective amount of a compound of Formula I, alone or in combination with other inhibitors of bone resorption, such as bisphosphonates (i.e., allendronate), hormone replacement therapy, anti-estrogens, or calcitonin.
  • a compound of Formula I alone or in combination with other inhibitors of bone resorption, such as bisphosphonates (i.e., allendronate), hormone replacement therapy, anti-estrogens, or calcitonin.
  • treatment with a compound of this invention and an anabolic agent, such as bone morphogenic protein, iproflavone may be used to prevent bone loss or to increase bone mass.
  • parenteral administration of a compound of Formula I is preferred.
  • the parenteral dose will be about 0.01 to about 100 g/kg; preferably between 0.1 and 20 mg/kg, in a manner to maintain the concentration of drug in the plasma at a concentration effective to inhibit cathepsin K.
  • the compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day.
  • the precise amount of an inventive compound which is therapeutically effective, and the route by which such compound is best administered, is readily determined by one of ordinary skill in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
  • the compounds of this invention may also be administered orally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption or to achieve any other therapeutic indication as disclosed herein.
  • a pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient.
  • the oral dose would be about 0.5 to about 20 mg/kg.
  • the compounds of this invention may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.
  • v is the velocity of the reaction with maximal velocity V m
  • A is the concentration of substrate with Michaelis constant of K a
  • / is the concentration of inhibitor
  • [AMC] v ss t + (vo - v ss ) [1 - exp (-k 0 b s t)J ' 'k 0 bs ( 2 )
  • the cells were washed x2 with cold RPMI-1640 by centrifugation (1000 rpm, 5 min at 4°C) and then transferred to a sterile 15 mL centrifuge tube.
  • the number of mononuclear cells were enumerated in an improved Neubauer counting chamber.
  • Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG, were removed from their stock bottle and placed into 5 mL of fresh medium (this washes away the toxic azide preservative). The medium was removed by immobilizing the beads on a magnet and is replaced with fresh medium.
  • the beads were mixed with the cells and the suspension was incubated for 30 min on ice. The suspension was mixed frequently. The bead-coated cells were immobilized on a magnet and the remaining cells (osteoclast-rich fraction) were decanted into a sterile 50 mL centrifuge tube. Fresh medium was added to the bead-coated cells to dislodge any trapped osteoclasts. This wash process was repeated xlO. The bead-coated cells were discarded. The osteoclasts were enumerated in a counting chamber, using a large-bore disposable plastic pasteur pipette to charge the chamber with the sample.
  • the cells were pelleted by centrifugation and the density of osteoclasts adjusted to 1.5xl0 4 /mL in EMEM medium, supplemented with 10% fetal calf serum and 1.7g/litre of sodium bicarbonate. 3 mL aliquots of the cell suspension ( per treatment) were decanted into 15 mL centrifuge tubes. These cells were pelleted by centrifugation. To each tube 3 mL of the appropriate treatment was added (diluted to 50 uM in the EMEM medium). Also included were appropriate vehicle controls, a positive control (87MEM1 diluted to 100 ug/mL) and an isotype control (IgG2a diluted to 100 ug/mL).
  • the tubes were incubate at 37°C for 30 min. 0.5 mL aliquots of the cells were seeded onto sterile dentine slices in a 48-well plate and incubated at 37°C for 2 h. Each treatment was screened in quadruplicate. The slices were washed in six changes of warm PBS (10 mL / well in a 6- well plate) and then placed into fresh treatment or control and incubated at 37°C for 48 h. The slices were then washed in phosphate buffered saline and fixed in 2% glutaraldehyde (in 0.2M sodium cacodylate) for 5 min., following which they were washed in water and incubated in buffer for 5 min at 37°C.
  • the slices were then washed in cold water and incubated in cold acetate buffer / fast red garnet for 5 min at 4°C. Excess buffer was aspirated, and the slices were air dried following a wash in water.
  • the TRAP positive osteoclasts were enumerated by bright-field microscopy and were then removed from the surface of the dentine by sonication. Pit volumes were determined using the Nikon/Lasertec ILM21 W confocal microscope.
  • reaction mixture was stirred until complete by TLC analysis (ca. 30 mins.). 30% HBr in AcOH (15 mL) was added dropwise at - 0°C. The reaction mixture was stirred at this temperature until complete as consumption of the starting material was observed (TLC). The reaction mixture was then diluted with ether, washed with water, aq. sat. NaHC0 3 , brine, dried (magnesium sulfate), filtered, concentrated in vacuo to provide 8.47 g of [l-(2-brorno-acetyl)but-3-enyl]-carbamic acid terr-butyl ester. This material was used in the next reaction without further purification.
  • Example la Following the procedures of Example la-i except substituting N-Boc-L- allylglycine for N-Boc-(D, L)-allylglycine of Example la, the title compound was prepared.
  • Example 14b To a solution of the acid of Example 14b (0.2 g, 1.1 mmol) in toluene (10 mL) was added triethylamine (0.15 mL, 1.1 mmol) followed by diphenylphosphoryl azide (0.23 mL,
  • Example 14d To a solution of the olefin of Example 14d (0.6 g) in CH3OH (20 mL) under nitrogen was added 10% Pd/C (150 mg). The mixture was evacuated and stirred under a balloon atmosphere of hydrogen overnight whereupon the mixture was filtered through a pad of celite with CH Cl , concentrated and chromatographed (3:1 ethyl acetate:hexanes) to provide 496 mg of the title compound as an off-white powder.
  • Example 14f The compound of Example 14f (0.1 g) was suspended in 4M HCl/dioxane (1.1 mL) until complete consumption of the starting material. The reaction was concentrated and azeotroped with toluene to provide the title compound (0.075 g).
  • Example 14g Following the procedure of Example lh except substituting the compound of Example 14g the title compound was prepared.
  • Example 14j Following the procedure of Example lh except substituting the compound of Example 14j and 5,6-dimethoxybenzofuran-2-carboxylic acid for N-Boc-leucine the title compound was prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des inhibiteurs de protéase à l'éther ayant une chaîne comprenant entre 7 et 14 éléments, y compris les sels pharmaceutiquement acceptables, les hydrates et les solvates correspondants, qui inhibent les protéases, y compris la cathepsine K. L'invention concerne en outre des compositions pharmaceutiques à base de ces composés, de nouveaux intermédiaires de ces composés, et des procédés relatifs au traitement des maladies caractérisées par une perte osseuse excessive ou bien par une dégradation excessive de cartilage ou de matrice, y compris l'ostéoporose; des maladies gingivales, y compris la gingivite et la parodontite; de l'arthrite, et plus précisément l'arthrose et la polyarthrite rhumatoïde; de la maladie de Paget; de l'hypercalcémie de la malignité; et des maladies métaboliques osseuses. On inhibe la perte osseuse excessive ou bien la dégradation excessive de cartilage ou de matrice en administrant au patient le type de composé considéré.
EP00910222A 1999-02-19 2000-02-17 Inhibiteurs de protease Withdrawn EP1153022A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12069999P 1999-02-19 1999-02-19
US120699P 1999-02-19
PCT/US2000/004133 WO2000049011A1 (fr) 1999-02-19 2000-02-17 Inhibiteurs de protease

Publications (2)

Publication Number Publication Date
EP1153022A1 true EP1153022A1 (fr) 2001-11-14
EP1153022A4 EP1153022A4 (fr) 2002-03-27

Family

ID=22392011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910222A Withdrawn EP1153022A4 (fr) 1999-02-19 2000-02-17 Inhibiteurs de protease

Country Status (8)

Country Link
EP (1) EP1153022A4 (fr)
JP (1) JP2002537297A (fr)
AU (1) AU3235100A (fr)
CO (1) CO5271679A1 (fr)
DZ (1) DZ3083A1 (fr)
HK (1) HK1042695A1 (fr)
PE (1) PE20001486A1 (fr)
WO (1) WO2000049011A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7168084B1 (en) 1992-12-09 2007-01-23 Sedna Patent Services, Llc Method and apparatus for targeting virtual objects
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1232155A4 (fr) 1999-11-10 2002-11-20 Smithkline Beecham Corp Inhibiteurs de protease
WO2001034600A1 (fr) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Inhibiteurs de protease
JP2003513924A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
SK13632002A3 (sk) 2000-03-21 2003-02-04 Smithkline Beecham Corporation C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
DE60118793T2 (de) * 2000-11-17 2007-04-26 Medivir Ab Cystein protease inhibitoren
EP1345931A2 (fr) * 2000-11-17 2003-09-24 Medivir UK Ltd Inhibiteurs de cysteine protease
EP1482020B1 (fr) * 2003-05-27 2006-09-06 MERCK PATENT GmbH Dérivés de pyrane avec une double liaison exocyclique
DE102004021338A1 (de) 2003-05-27 2005-03-03 Merck Patent Gmbh Pyranderivate
EP1757284A1 (fr) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Utilisation de la N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) pour la prévention ou le traitement de la dystrophie musculaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021432A (en) * 1988-04-26 1991-06-04 Yoshitomi Pharmaceutical Industries, Ltd. Benzopyran compound and its pharmaceutical use
CA2157412A1 (fr) * 1993-03-03 1994-09-15 Julia Marie Heerding Balanoides
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO0049011A1 *

Also Published As

Publication number Publication date
WO2000049011A1 (fr) 2000-08-24
EP1153022A4 (fr) 2002-03-27
DZ3083A1 (fr) 2004-06-02
CO5271679A1 (es) 2003-04-30
HK1042695A1 (zh) 2002-08-23
JP2002537297A (ja) 2002-11-05
AU3235100A (en) 2000-09-04
PE20001486A1 (es) 2001-02-08

Similar Documents

Publication Publication Date Title
US7071184B2 (en) Protease inhibitors
AU2001243441A1 (en) Protease inhibitors
NZ337889A (en) Cysteine Protease inhibitors of the Papain superfamily comprising cathepsin K protease inhibitors
WO1998008802A1 (fr) Inhibiteurs de cysteine protease
WO2000049011A1 (fr) Inhibiteurs de protease
EP1079821A1 (fr) Inhibiteurs de la protease
US20020049316A1 (en) Protease inhibitors
WO2000039115A1 (fr) Inhibiteurs de proteases
EP1173429A1 (fr) Inhibiteurs de protease
EP1161237A1 (fr) Inhibiteurs de protease
US20020165222A1 (en) Protease inhibitors
US20040157828A1 (en) Protease inhibitors
US20050256100A1 (en) Protease inhibitors
EP1384713B1 (fr) Derives de 4-amino-azepan-3-one comme inhibiteurs de protease
EP1392657A2 (fr) Inhibiteurs de la protease
US20050256105A1 (en) Protease inhibitors
US20050203084A1 (en) Protease inhibitors
US7109233B2 (en) Protease inhibitors
WO2003103574A2 (fr) Inhibiteurs de protease
US20040038965A1 (en) Protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010711

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020208

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 313/04 A, 7C 07D 333/70 B, 7C 07D 241/36 B, 7C 07D 209/42 B, 7A 61K 31/336 B, 7A 61K 31/381 B, 7A 61K 31/498 B, 7A 61K 31/404 B, 7C 07D 498/04 B, 7C 07D 313/18 B, 7C 07D 409/12 B, 7C 07D 407/12 B, 7C 07D 405/12 B, 7A 61K 31/38 B, 7A 61K 31/34 B, 7A 61K 31/40 B, 7A 61K 31/47 B, 7A 61K 31/495 B

17Q First examination report despatched

Effective date: 20020513

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021126

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1042695

Country of ref document: HK